Ignite Creation Date:
2025-12-25 @ 3:09 AM
Ignite Modification Date:
2026-01-27 @ 2:34 AM
Study NCT ID:
NCT00492505
Status:
UNKNOWN
Last Update Posted:
2014-01-10
First Post:
2007-06-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008545', 'term': 'Melanoma'}], 'ancestors': [{'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D018326', 'term': 'Nevi and Melanomas'}, {'id': 'D012878', 'term': 'Skin Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D002945', 'term': 'Cisplatin'}, {'id': 'D000077157', 'term': 'Sorafenib'}, {'id': 'D013629', 'term': 'Tamoxifen'}, {'id': 'D017024', 'term': 'Chemotherapy, Adjuvant'}], 'ancestors': [{'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017672', 'term': 'Nitrogen Compounds'}, {'id': 'D017671', 'term': 'Platinum Compounds'}, {'id': 'D010671', 'term': 'Phenylurea Compounds'}, {'id': 'D014508', 'term': 'Urea'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009536', 'term': 'Niacinamide'}, {'id': 'D009539', 'term': 'Nicotinic Acids'}, {'id': 'D000147', 'term': 'Acids, Heterocyclic'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D013267', 'term': 'Stilbenes'}, {'id': 'D001597', 'term': 'Benzylidene Compounds'}, {'id': 'D003131', 'term': 'Combined Modality Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D004358', 'term': 'Drug Therapy'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'primaryPurpose': 'TREATMENT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 200}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2007-04'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2009-07', 'lastUpdateSubmitDate': '2014-01-09', 'studyFirstSubmitDate': '2007-06-25', 'studyFirstSubmitQcDate': '2007-06-25', 'lastUpdatePostDateStruct': {'date': '2014-01-10', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2007-06-27', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2011-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Relapse-free survival'}, {'measure': 'Overall survival'}, {'measure': 'Toxicity'}]}, 'conditionsModule': {'keywords': ['stage IIIA melanoma', 'stage IIIB melanoma', 'stage IIIC melanoma'], 'conditions': ['Melanoma (Skin)']}, 'descriptionModule': {'briefSummary': 'RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as tamoxifen and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with tamoxifen and cisplatin after surgery may kill any tumor cells that remain after surgery.\n\nPURPOSE: This phase II trial is studying the side effects and how well giving sorafenib together with tamoxifen and cisplatin works in treating patients with high-risk stage III melanoma.', 'detailedDescription': 'OBJECTIVES:\n\n* Compare relapse-free and overall survival of patients with high-risk stage III melanoma receiving adjuvant sorafenib tosylate, tamoxifen citrate, and cisplatin vs historical data from patients treated with tamoxifen citrate and cisplatin.\n* Compare the toxicity of these regimens in these patients.\n\nOUTLINE: This is a pilot study. Patients are stratified according to number of positive lymph nodes identified during surgery.\n\nPatients receive oral sorafenib tosylate twice daily on days 1-28, oral tamoxifen citrate twice daily on days 1-7, and cisplatin IV over 1 hour on days 2 and 3. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study therapy, patients are followed periodically for at least 5 years.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "DISEASE CHARACTERISTICS:\n\n* Confirmed diagnosis of melanoma\n\n * High-risk, stage III disease\n* No measurable metastatic disease\n* Has undergone surgery within the past 8 weeks\n\n * Surgically rendered disease free\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Creatinine clearance ≥ 50 mL/min OR creatinine ≤ 1.5 mg/dL\n* Liver function tests ≤ 3 times the upper limit of normal\n* ANC ≥ 1,200/mm³\n* Hemoglobin ≥ 9.0 g/dL\n* Platelet count ≥ 100,000/mm³\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No myocardial infarction within the past 6 months\n* No congestive heart failure requiring medication\n* No pulmonary disease requiring supplemental oxygen\n* No dyspnea at rest\n* No active infection\n* No chronic underlying immunodeficiency disease\n* No other serious illness that, in the physicians' opinion, may compromise the safety of the patient\n* No other cancer within the past 5 years except for nonmelanoma skin cancer and cervical cancer\n* No thromboembolic disease within the past 6 months\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior tamoxifen citrate, sorafenib tosylate, or cisplatin\n* No concurrent radiotherapy or surgery"}, 'identificationModule': {'nctId': 'NCT00492505', 'briefTitle': 'Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma', 'organization': {'class': 'NIH', 'fullName': 'National Cancer Institute (NCI)'}, 'officialTitle': 'A Phase II Pilot Trial of Sorafenib, Tamoxifen and Cisplatin as Adjuvant Therapy for Patients With Stage III Malignant Melanoma', 'orgStudyIdInfo': {'id': 'CDR0000551556'}, 'secondaryIdInfos': [{'id': 'POHA-0602'}]}, 'armsInterventionsModule': {'interventions': [{'name': 'cisplatin', 'type': 'DRUG'}, {'name': 'sorafenib tosylate', 'type': 'DRUG'}, {'name': 'tamoxifen citrate', 'type': 'DRUG'}, {'name': 'adjuvant therapy', 'type': 'PROCEDURE'}]}, 'contactsLocationsModule': {'locations': [{'zip': '92024', 'city': 'Encinitas', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Edward F. McClay, MD', 'role': 'CONTACT', 'email': 'emcclay@pacificoncology.com', 'phone': '760-452-3340'}], 'facility': 'San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas', 'geoPoint': {'lat': 33.03699, 'lon': -117.29198}}], 'overallOfficials': [{'name': 'Edward F. McClay, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'San Diego Pacific Oncology & Hematology Associates'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'San Diego Pacific Oncology & Hematology Associates', 'class': 'OTHER'}}}}